EZH2, an on-off valve in signal network of tumor cells

Cellular Signalling

Volumn 28, Issue 5, 2016, Pages 481-487

  Sun, Shanshan ^a   Yu, Feng ^a   Zhang, Lun ^a   Zhou, Xuan ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Double facet; EZH2; Histone modulation; Signaling; Tumor

Indexed keywords

MICRORNA; TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN;

CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL MIGRATION; DRUG TARGETING; EPIGENETICS; GENE ACTIVATION; GENE SILENCING; GENE TARGETING; GLIOBLASTOMA; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN RNA BINDING; REVIEW; TRANSCRIPTION INITIATION; TUMOR CELL; TUMOR INVASION; TUMOR VASCULARIZATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NEOPLASM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MICE; MICRORNAS; NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84958531825     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2016.02.004     Document Type: Review

References (99)

1. Wu L., Murat P., Matak-Vinkovic D., Murrell A., Balasubramanian S. Binding interactions between long noncoding RNA HOTAIR and PRC2 proteins. Biochemistry 2013, 52:9519-9527.
2. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
3. Rinn J.L., Kertesz M., Wang J.K., Squazzo S.L., Xu X., Brugmann S.A., et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007, 129:1311-1323.
4. Ringrose L., Paro R. Polycomb/trithorax response elements and epigenetic memory of cell identity. Development 2007, 134:223-232.
5. Mills A.A. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat. Rev. Cancer 2010, 10:669-682.
6. Xu Z.Q., Zhang L., Gao B.S., Wan Y.G., Zhang X.H., Chen B., et al. EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma. Clin. Transl. Oncol.: Off. Publ. Fed. Span. Oncol. Soc. Nat. Cancer Inst. Mex. 2015, 17:41-49.
7. Kim K.H., Kim L., Choi S.J., Han J.Y., Kim J.M., Chu Y.C., et al. The clinicopathological significance of epithelial mesenchymal transition associated protein expression in head and neck squamous cell carcinoma. Kor. J. Pathol. 2014, 48:263-269.
8. Ahani N., Shirkoohi R., Rokouei M., Alipour Eskandani M., Nikravesh A. Overexpression of enhancer of zeste human homolog 2 (EZH2) gene in human cytomegalovirus positive glioblastoma multiforme tissues. Med. Oncol. 2014, 31:252.
9. Chisholm K.M., Wan Y., Li R., Montgomery K.D., Chang H.Y., West R.B. Detection of long non-coding RNA in archival tissue: correlation with polycomb protein expression in primary and metastatic breast carcinoma. PLoS One 2012, 7.
10. Reijm E.A., Timmermans A.M., Look M.P., Meijer-van Gelder M.E., Stobbe C.K., van Deurzen C.H., et al. High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO 2014, 25:2185-2190.
11. Benard A., Goossens-Beumer I.J., van Hoesel A.Q., Horati H., Putter H., Zeestraten E.C., et al. Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 in colorectal cancer. PLoS One 2014, 9.
12. Lu J., Zhao F.P., Peng Z., Zhang M.W., Lin S.X., Liang B.J., et al. EZH2 promotes angiogenesis through inhibition of miR-1/endothelin-1 axis in nasopharyngeal carcinoma. Oncotarget 2014, 5:11319-11332.
13. Tang B., Du J., Li Y., Tang F., Wang Z., He S. EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3. Med. Oncol. 2014, 31:271.
14. Yu H., Simons D.L., Segall I., Carcamo-Cavazos V., Schwartz E.J., Yan N., et al. PRC2/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ. PLoS One 2012, 7.
15. Suva M.L., Riggi N., Janiszewska M., Radovanovic I., Provero P., Stehle J.C., et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 2009, 69:9211-9218.
16. Jia N., Li Q., Tao X., Wang J., Hua K., Feng W. Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma. Oncol. Lett. 2014, 8:2049-2054.
17. Xu C., Hao K., Hu H., Sheng Z., Yan J., Wang Q., et al. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy. Lung Cancer 2014, 86:268-273.
18. Tiwari N., Tiwari V.K., Waldmeier L., Balwierz P.J., Arnold P., Pachkov M., et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 2013, 23:768-783.
19. Liu X., Wang C., Chen Z., Jin Y., Wang Y., Kolokythas A., et al. MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem. J. 2011, 440:23-31.
20. Nolan K.D., Franco O.E., Hance M.W., Hayward S.W., Isaacs J.S. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion. J. Biol. Chem. 2015, 290:8271-8282.
21. Tong Z.T., Cai M.Y., Wang X.G., Kong L.L., Mai S.J., Liu Y.H., et al. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and snail to inhibit E-cadherin. Oncogene 2012, 31:583-594.
22. Chen J., Xu H., Zou X., Wang J., Zhu Y., Chen H., et al. Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells. Cancer Res. 2014, 74:4353-4363.
23. Fujii S., Tokita K., Wada N., Ito K., Yamauchi C., Ito Y., et al. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene 2011, 30:4118-4128.
24. Fujii S., Ito K., Ito Y., Ochiai A. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J. Biol. Chem. 2008, 283:17324-17332.
25. Fujii S., Ochiai A. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci. 2008, 99:738-746.
26. Foster C.S., Falconer A., Dodson A.R., Norman A.R., Dennis N., Fletcher A., et al. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 2004, 23:5871-5879.
27. Tsai M.C., Manor O., Wan Y., Mosammaparast N., Wang J.K., Lan F., et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010, 329:689-693.
28. Santos M., Martinez-Fernandez M., Duenas M., Garcia-Escudero R., Alfaya B., Villacampa F., et al. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer. Cancer Res. 2014, 74:6565-6577.
29. Hwang-Verslues W.W., Chang P.H., Jeng Y.M., Kuo W.H., Chiang P.H., Chang Y.C., et al. Loss of corepressor PER2 under hypoxia up-regulates OCT1-mediated EMT gene expression and enhances tumor malignancy. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:12331-12336.
30. Ferraro A., Mourtzoukou D., Kosmidou V., Avlonitis S., Kontogeorgos G., Zografos G., et al. EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control epithelial-mesenchymal transition and anoikis in colon cancer cells. Int. J. Biochem. Cell Biol. 2013, 45:243-254.
31. Fiskus W., Wang Y., Sreekumar A., Buckley K.M., Shi H., Jillella A., et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009, 114:2733-2743.
32. Zhang Y., Tong T. FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis. Biochem. Biophys. Res. Commun. 2014, 453:172-178.
33. Cui B., Yang Q., Guan H., Shi B., Hou P., Ji M. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-deazaneplanocin A. J. Clin. Endocrinol. Metab. 2014, 99:E962-E970.
34. Fu H.L., Ma Y., Lu L.G., Hou P., Li B.J., Jin W.L., et al. TET1 exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer. J. Biomed. Nanotechnol. 2014, 10:1217-1230.
35. Bai J., Ma M., Cai M., Xu F., Chen J., Wang G., et al. Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin in p53 mutant gastric cancer cells. Cell Prolif. 2014, 47:211-218.
36. Wu Z., Lee S.T., Qiao Y., Li Z., Lee P.L., Lee Y.J., et al. Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ. 2011, 18:1771-1779.
37. Wee Z.N., Li Z., Lee P.L., Lee S.T., Lim Y.P., Yu Q. EZH2-mediated inactivation of IFN-gamma-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer. Cell Rep. 2014, 8:204-216.
38. Qiu S., Huang D., Yin D., Li F., Li X., Kung H.F., et al. Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme. Biochim. Biophys. Acta 1832, 2013:1697-1707.
39. Coe B.P., Thu K.L., Aviel-Ronen S., Vucic E.A., Gazdar A.F., Lam S., et al. Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer. PLoS One 2013, 8.
40. Tang X., Milyavsky M., Shats I., Erez N., Goldfinger N., Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004, 23:5759-5769.
41. Bai J., Chen J., Ma M., Cai M., Xu F., Wang G., et al. Inhibiting enhancer of zeste homolog 2 promotes cellular senescence in gastric cancer cells SGC-7901 by activation of p21 and p16. DNA Cell Biol. 2014, 33:337-344.
42. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003, 22:5323-5335.
43. Iannetti A., Ledoux A.C., Tudhope S.J., Sellier H., Zhao B., Mowla S., et al. Regulation of p53 and Rb links the alternative NF-kappaB pathway to EZH2 expression and cell senescence. PLoS Genet. 2014, 10.
44. Wu Z.L., Zheng S.S., Li Z.M., Qiao Y.Y., Aau M.Y., Yu Q. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating bim expression. Cell Death Differ. 2010, 17:801-810.
45. Mu Z., Li H., Fernandez S.V., Alpaugh K.R., Zhang R., Cristofanilli M. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. J. Exp. Clin. Cancer Res. CR 2013, 32:70.
46. Sun J., Zheng G., Gu Z., Guo Z. MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2. J. Neuro-Oncol. 2015, 122:481-489.
47. Yoo K.H., Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer. Int. J. Biol. Sci. 2012, 8:59-65.
48. Mitic T., Caporali A., Floris I., Meloni M., Marchetti M., Urrutia R., et al. EZH2 modulates angiogenesis in vitro and in a mouse model of limb ischemia. Mol. Ther.:J. Am. Soc. Gene Ther. 2015, 23:32-42.
49. Simon C., Chagraoui J., Krosl J., Gendron P., Wilhelm B., Lemieux S., et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 2012, 26:651-656.
50. Mallen-St Clair J., Soydaner-Azeloglu R., Lee K.E., Taylor L., Livanos A., Pylayeva-Gupta Y., et al. EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev. 2012, 26:439-444.
51. Kim E., Kim M., Woo D.H., Shin Y., Shin J., Chang N., et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013, 23:839-852.
52. Fouse S.D., Costello J.F. Cancer stem cells activate STAT3 the EZ Way. Cancer Cell 2013, 23:711-713.
53. Xu K., Wu Z.J., Groner A.C., He H.H., Cai C., Lis R.T., et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. Science 2012, 338:1465-1469.
54. Yan J., Ng S.B., Tay J.L., Lin B., Koh T.L., Tan J., et al. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood 2013, 121:4512-4520.
55. Gonzalez M.E., Moore H.M., Li X., Toy K.A., Huang W., Sabel M.S., et al. EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:3098-3103.
56. Jung H.Y., Jun S., Lee M., Kim H.C., Wang X., Ji H., et al. PAF and EZH2 induce Wnt/beta-catenin signaling hyperactivation. Mol. Cell 2013, 52:193-205.
57. Lee S.T., Li Z., Wu Z., Aau M., Guan P., Karuturi R.K., et al. Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers. Mol. Cell 2011, 43:798-810.
58. Lei Q., Shen F., Wu J., Zhang W., Wang J., Zhang L. MiR-101, downregulated in retinoblastoma, functions as a tumor suppressor in human retinoblastoma cells by targeting EZH2. Oncol. Rep. 2014, 32:261-269.
59. Sander S., Bullinger L., Klapproth K., Fiedler K., Kestler H.A., Barth T.F., et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008, 112:4202-4212.
60. Varambally S., Cao Q., Mani R.S., Shankar S., Wang X., Ateeq B., et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322:1695-1699.
61. Liu T., Hou L., Huang Y. EZH2-specific microRNA-98 inhibits human ovarian cancer stem cell proliferation via regulating the pRb-E2F pathway. Tumour Biol.: J. Int. Soc. Oncodev. Biol. Med. 2014, 35:7239-7247.
62. Guo Y., Ying L., Tian Y., Yang P., Zhu Y., Wang Z., et al. miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling. FEBS J. 2013, 280:4531-4538.
63. Karoopongse E., Yeung C., Byon J., Ramakrishnan A., Holman Z.J., Jiang P.Y., et al. The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy. PLoS One 2014, 9.
64. Liu L., Guo J., Yu L., Cai J., Gui T., Tang H., et al. miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer. Tumour Biol.: J. Int. Soc. Oncodev. Biol. Med. 2014, 35:12619-12626.
65. Zhang D., Ni Z., Xu X., Xiao J. MiR-32 functions as a tumor suppressor and directly targets EZH2 in human oral squamous cell carcinoma. Med. Sci. Monit.: Int. Med. J. Exp. Clin. Res. 2014, 20:2527-2535.
66. Lin L., Zheng Y., Tu Y., Wang Z., Liu H., Lu X., et al. MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2. Hum. Pathol. 2015, 46:971-980.
67. Liu F., He Y., Shu R., Wang S. MicroRNA-1297 regulates hepatocellular carcinoma cell proliferation and apoptosis by targeting EZH2. Int. J. Clin. Exp. Pathol. 2015, 8:4972-4980.
68. Hibino S., Saito Y., Muramatsu T., Otani A., Kasai Y., Kimura M., et al. Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells. Oncogenesis 2014, 3.
69. Huang D., Qiu S., Ge R., He L., Li M., Li Y., et al. miR-340 suppresses glioblastoma multiforme. Oncotarget 2015, 6:9257-9270.
70. Zhao X., Lwin T., Zhang X., Huang A., Wang J., Marquez V.E., et al. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia 2013, 27:2341-2350.
71. Tao T., Liu D., Liu C., Xu B., Chen S., Yin Y., et al. Autoregulatory feedback loop of EZH2/miR-200c/E2F3 as a driving force for prostate cancer development. Biochim. Biophys. Acta 1839, 2014:858-865.
72. Koumangoye R.B., Andl T., Taubenslag K.J., Zilberman S.T., Taylor C.J., Loomans H.A., et al. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells. Mol. Cancer 2015, 14:24.
73. Cha T.L., Zhou B.P., Xia W., Wu Y., Yang C.C., Chen C.T., et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005, 310:306-310.
74. Chen B., Liu J., Chang Q., Beezhold K., Lu Y., Chen F. JNK and STAT3 signaling pathways converge on Akt-mediated phosphorylation of EZH2 in bronchial epithelial cells induced by arsenic. Cell Cycle 2013, 12:112-121.
75. Li L., Qiu P., Chen B., Lu Y., Wu K., Thakur C., et al. Reactive oxygen species contribute to arsenic-induced EZH2 phosphorylation in human bronchial epithelial cells and lung cancer cells. Toxicol. Appl. Pharmacol. 2014, 276:165-170.
76. Lin Y.W., Ren L.L., Xiong H., Du W., Yu Y.N., Sun T.T., et al. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer. J. Pathol. 2013, 230:277-290.
77. Feng H., Yu Z., Tian Y., Lee Y.Y., Li M.S., Go M.Y., et al. A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients. J. Hepatol. 2015, 62:1100-1111.
78. Wu S.C., Zhang Y. Cyclin-dependent kinase 1 (CDK1)-mediated phosphorylation of enhancer of zeste 2 (Ezh2) regulates its stability. J. Biol. Chem. 2011, 286:28511-28519.
79. Kaneko S., Li G., Son J., Xu C.F., Margueron R., Neubert T.A., et al. Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev. 2010, 24:2615-2620.
80. Van Hoof D., Munoz J., Braam S.R., Pinkse M.W., Linding R., Heck A.J., et al. Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 2009, 5:214-226.
81. Wei Y., Chen Y.H., Li L.Y., Lang J., Yeh S.P., Shi B., et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat. Cell Biol. 2011, 13:87-94.
82. Chen S., Bohrer L.R., Rai A.N., Pan Y., Gan L., Zhou X., et al. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat. Cell Biol. 2010, 12:1108-1114.
83. Yang C.C., LaBaff A., Wei Y., Nie L., Xia W., Huo L., et al. Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. Am. J. Transl. Res. 2015, 7:1009-1020.
84. Liu T.P., Lo H.L., Wei L.S., Hsiao H.H., Yang P.M. S-adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells. Anti-Cancer Drugs 2015, 26:139-147.
85. Girard N., Bazille C., Lhuissier E., Benateau H., Llombart-Bosch A., Boumediene K., et al. 3-deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells. PLoS One 2014, 9.
86. Tan J., Yang X., Zhuang L., Jiang X., Chen W., Lee P.L., et al. Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007, 21:1050-1063.
87. Hayden A., Johnson P.W., Packham G., Crabb S.J. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res. Treat. 2011, 127:109-119.
88. Kikuchi J., Takashina T., Kinoshita I., Kikuchi E., Shimizu Y., Sakakibara-Konishi J., et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer 2012, 78:138-143.
89. Lee J.K., Kim K.C. DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells. Biochem. Biophys. Res. Commun. 2013, 438:647-652.
90. Ueda K., Yoshimi A., Kagoya Y., Nishikawa S., Marquez V.E., Nakagawa M., et al. Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16. Cancer Sci. 2014, 105:512-519.
91. Simon J.A., Lange C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 2008, 647:21-29.
92. Verma S.K., Tian X., LaFrance L.V., Duquenne C., Suarez D.P., Newlander K.A., et al. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med. Chem. Lett. 2012, 3:1091-1096.
93. Qi W., Chan H., Teng L., Li L., Chuai S., Zhang R., et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:21360-21365.
94. Wang L., Zeng X., Chen S., Ding L., Zhong J., Zhao J.C., Ma Y. BRCA1 is a negative modulator of the PRC2 complex. The EMBO journal 2013, 32:1584-1597.
95. Gupta R.A., Shah N., Wang K.C., Kim J., Horlings H.M., Wong D.J., Wang Y. "Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis.". Nature 2010, 464.7291:1071-1076.
96. Ciarapica R., De Salvo M., Carcarino E., Bracaglia G., Adesso L., Leoncini P.P., Boldrini R. "The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).". Oncogene 2014, 33.32:4173-4184.
97. Zhang Y., Tong T. FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis[J]. Biochemical and biophysical research communications 2014, 453(1):172-178.
98. Xu K., Wu Z.J., Groner A.C., He H.H., Cai C., Lis R.T., Xu H. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 2012, 338(6113):1465-1469.
99. Yan J., Ng S.B., Tay J.L.S., Lin B., Koh T.L., Tan J., Choo S.N. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood 2013, 121(22):4512-4520.